TY - JOUR AU - Metro, Giulio AU - Di Maio, Massimo PY - 2018 TI - Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? JF - Translational Lung Cancer Research; Vol 7, Supplement 3 (September 26, 2018): Translational Lung Cancer Research1 Y2 - 2018 KW - N2 - We agree with dr. Addeo and dr. Banna when they emphasize that the biology of non-small cell lung cancer (NSCLC) is complex, and that a single biomarker is probably not exhaustive in order to optimally predict (either positively or negatively) the potential efficacy of immune checkpoint inhibitors. UR - https://tlcr.amegroups.org/article/view/23045